Allyson Kinzel named senior vice president and chief legal officer at MD Anderson

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center has named Allyson Hancock Kinzel as senior vice president and chief legal officer, effective Nov. 1.

Kinzel will lead legal and regulatory affairs in her role after serving as chief legal officer since 2018. She will report to the president and will be a member of the institution’s executive leadership team.

As senior vice president, Kinzel will oversee three legal and regulatory departments: Legal Services, Internal Audit and the Office of Institutional Compliance. Kinzel will be responsible for identifying and managing risk across the institution, leading auditing and monitoring efforts and ensuring the institution’s compliance with federal and state laws. As chief legal officer, she has guided responses to hospital-wide federal regulatory surveys, established MD Anderson’s institutional conflict of interest policy and program structure and led the institution’s response to the Office for Civil Rights regarding federal enforcement provisions.

Before serving as chief legal officer, Kinzel worked for 10 years in Institutional Compliance at MD Anderson and was vice president and chief compliance and ethics officer from 2014 to 2018. Prior to coming to MD Anderson, Kinzel represented health care providers as a partner at Baker Hostetler, LLP, and as an attorney at Vinson and Elkins, LLP.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login